Healthcare holds up in Q3 as crop business drags on Bayer
This article was originally published in Scrip
Executive Summary
Growth in Bayer's healthcare sales in the third quarter failed to compensate for a very poor quarter for its crop science division – which was hit by falling crop commodity prices and adverse weather conditions – and a significant year-on-year decline in its materials science business, which declined by 20%.